Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.110
+0.220 (7.61%)
At close: Nov 12, 2025, 4:00 PM EST
3.120
+0.010 (0.32%)
After-hours: Nov 12, 2025, 4:17 PM EST
Ironwood Pharmaceuticals Employees
Ironwood Pharmaceuticals had 253 employees as of December 31, 2024. The number of employees decreased by 14 or -5.24% compared to the previous year.
Employees
253
Change (1Y)
-14
Growth (1Y)
-5.24%
Revenue / Employee
$1,339,870
Profits / Employee
$112,842
Market Cap
505.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 253 | -14 | -5.24% |
| Dec 31, 2023 | 267 | 48 | 21.92% |
| Dec 31, 2022 | 219 | 0 | - |
| Dec 31, 2021 | 219 | -13 | -5.60% |
| Dec 31, 2020 | 232 | -85 | -26.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRWD News
- 2 days ago - Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance - Business Wire
- 19 days ago - Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta - Accesswire
- 3 months ago - Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - Business Wire
- 6 months ago - Ironwood Pharmaceuticals Reports First Quarter 2025 Results - Business Wire
- 7 months ago - Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
- 7 months ago - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Business Wire
- 7 months ago - Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - Business Wire
- 7 months ago - Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga